AI specialists ink deal with Pfizer to target cardiac amyloidosis

Related Articles
Promising AI clinical use cases beyond imaging
Health Evolution: Researchers in Future Healthcare Journal say that while there are claims from organizations that they’ve developed an AI solution that can “diagnose and treat a disease with equal or…November 09, 2021
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 20, 2022
BOSTINNO’S 2021 INNO ON FIRE: Meet the 50 startups and individuals setting Boston’s innovation ecosystem ablaze.
Biz Journals: If 2020 was a strange year for Boston's startups, companies and nonprofits, 2021 was its equally weird sequel. But the continuing pandemic, global supply-chain shortages, economic turmoil and…November 10, 2021
Anumana partners with Novartis for AI-driven heart disease detection
Medical Device Network: Health technology company Anumana and Novartis Pharmaceuticals Corporation have entered a partnership to use artificial intelligence (AI) for the detection of heart diseases. Under the multi-year collaboration,…July 13, 2022


